AFP and cancer: CAFs were key pro-tumor components in the TME and were contributing to poor prognosis.46–48 However, some studies suggested that CAFs may acquire an anti-tumor phenotype and counteract tumor progression.49,50 Recent research emphasized that CAFs signaled immune cells in tumor niches, with perivascular CAFs recruiting T cells into the tumor.26 Our finding supported the aforementioned conclusions, suggesting that AFP-G/GEJ cancer may harbor a CAF subpopulation around blood vessels that recruited T cells into the tumor parenchyma.